Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era

• Published in: International journal of hematology Vol. 114; no. 2; pp. 189 - 198
• Main Authors: Sang, Wei, Zhou, Hang, Qin, Yuanyuan, Shen, Ziyuan, Yan, Dongmei, Sun, Cai, Song, Xuguang, Ma, Yuhan, Tu, Dongyun, Bian, Zhenzhen, Nie, Shanlin, Jin, Yingliang, Xu, Linyan, Li, Zhenyu, Xu, Kailin
• Format: Journal Article
• Language: English
• Published: Singapore Springer Singapore 01.08.2021; Springer Nature B.V
• Subjects: Angiogenesis; Bcl-2 protein; Growth factors; Hematology; Immunotherapy; Invasiveness; Lymphocytes B; Lymphoma; Medical prognosis; Medicine; Medicine & Public Health; Monoclonal antibodies; Myc protein; Oncology; Original Article; Patients; Rank tests; Risk; Risk groups; Rituximab; Solid tumors; Survival; Targeted cancer therapy; Tumors; Vascular endothelial growth factor; International prognostic index; Rituximab; Diffuse large B cell lymphoma; Prognosis; Vascular endothelial growth factor
• ISSN: 0925-5710; 1865-3774; 1865-3774
• DOI: 10.1007/s12185-021-03145-3

Vascular endothelial growth factor affects the invasiveness of solid tumors by regulating angiogenesis. However, it is not clear whether VEGF could be used to predict the prognosis of DLBCL in the era of rituximab-based immunotherapy. We conducted a retrospective study to explore response to therapy and the prognostic value of VEGF on DLBCL in the rituximab era. The subjects were 65 patients with a histological diagnosis of DLBCL from the Affiliated Hospital of Xuzhou Medical University. Kaplan–Meier analysis was performed to estimate the cumulative survival rate of patients with different VEGF and IPI levels, and comparisons between groups were made using the log-rank test. DLBCL patients with elevated VEGF were more likely to have extranodal involvement, advanced stage, Myc/Bcl-2 double expression, and a higher Ki-67 score. Elevated VEGF was associated with poor therapeutic response and survival. When patients were divided into low, low-intermediate, high-intermediate and high-risk groups using the V-IPI model based on VEGF and IPI, PFS rates were 94.4, 74.1, 40.6 and 14.8%, respectively. This model better identified low-risk patients than IPI (85.9, 88.9, 37 and 7.8%). Our results demonstrate that VEGF predicts therapeutic response in DLBCL and the V-IPI model accurately predicts PFS of low-risk DLBCL in the rituximab era.